Imcyse S.A.
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
7
Ending by 2030
Apr 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 2, 2026The maintenance fee for Elimination of immune responses to viral vectors (US 9,044,507) comes due Dec 2, 2026. Unpaid by Jun 2, 2027, it lapses early.
- 1 fee due Feb 8, 2027The maintenance fee for Immunogenic Peptides and Their Use in Immune Disorders (US 11,718,650) comes due Feb 8, 2027. Unpaid by Aug 9, 2027, it lapses early.
- 1 fee due Apr 17, 2027The maintenance fee for Improved Methods and Compounds for Eliminating Immune Responses to Therapeutic Agents (US 11,787,849) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
- 2 fees due Aug 2, 2027
- 1 fee due Oct 14, 2027The maintenance fee for Immunogenic control of tumours and tumour cells (US 10,617,748) comes due Oct 14, 2027. Unpaid by Apr 14, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,662,232 | Immunogenic Peptides and Their Use in Immune Disorders In force · High confidence | In force | High confidence | |
| US 11,718,650 | Immunogenic Peptides and Their Use in Immune Disorders In force · High confidence | In force | High confidence | |
| US 9,248,171 | Immunogenic peptides and their use in transplantation In force · USPTO record | In force | USPTO record | |
| US 10,617,748 | Immunogenic control of tumours and tumour cells In force · USPTO record | In force | USPTO record | |
| US 9,044,507 | Elimination of immune responses to viral vectors In force · USPTO record | In force | USPTO record | |
| US 9,394,517 | CD4+ T-cells with cytolytic properties In force · USPTO record | In force | USPTO record | |
| US 8,999,346 | Immunogenic control of tumours and tumour cells In force · USPTO record | In force | USPTO record | |
| US 9,249,202 | Immunogenic Peptides and Their Use in Immune Disorders In force · High confidence | In force | High confidence | |
| US 12,023,384 | Immunogenic Peptides Comprising an MHC class II T Cell Epitope and a Redox Motif In force · Medium confidence | In force | Medium confidence | |
| US 10,729,791 | Animal models for evaluating pharmaceutical compounds In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 12: 3 patents in force now held by others · 6 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 6 abandoned · 13 no status recorded
Showing 1 to 10 of 23, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/674,092 | Novel Immunogenic Peptides | May 24, 2024 | Pending |
| 18/410,001 | Jan 11, 2024 | No status recorded | |
| 18/542,031 | Dec 15, 2023 | Abandoned | |
| 18/462,035 | Methods and Compounds for Eliminating Immune Responses to Therapeutic Agents | Sep 6, 2023 | Pending |
| 18/342,897 | Jun 28, 2023 | No status recorded | |
| 18/332,985 | Jun 12, 2023 | Abandoned | |
| 17/934,607 | Sep 23, 2022 | No status recorded | |
| 18/564,985 | Jun 1, 2022 | No status recorded | |
| 18/563,288 | Methods of Treating or Preventing Autoimmune Diseases | May 25, 2022 | Abandoned |
| 17/517,805 | Immunogenic Peptides for Use in the Prevention And/Or Treatment of Infectious Diseases, Autoimmune Diseases, Immune Responses to Allofactors, Allergic Diseases, Tumors, Graft Rejection and Immune Responses Against Viral Vectors Used for Gene Therapy or Gene Vaccination | Nov 3, 2021 | Abandoned |
10 of 23 applications shown.
Pro members see all 23 published applications.